References
Yamato G, Deguchi T, Terui K, Toki T, Watanabe T, Imaizumi T, et al. Predictive factors for the development of leukemia in patients with transient abnormal myelopoiesis and Down syndrome. Leukemia. 2021;35(5):1480–4.
Bhatnagar N, Nizery L, Tunstall O, Vyas P, Roberts I. Transient abnormal myelopoiesis and AML in Down syndrome: An update. Curr Hematol Malig Rep. 2016;11(5):333–41
Tunstall O, Bhatnagar N, James B, Norton A, O’Marcaigh AS, Watts T, et al. Guidelines for the investigation and management of Transient Leukaemia of Down Syndrome. Br J Haematol. 2018;182(2):200–11
Klusmann J-H, Creutzig U, Zimmermann M, Dworzak M, Jorch N, Langebrake C, et al. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. Blood. 2008;111(6):2991–8.
Gamis AS, Smith FO. Transient myeloproliferative disorder in children with Down syndrome: clarity to this enigmatic disorder. Br J Haematol. 2012;159(3):277–87.
Al-Ahmari A, Shah N, Sung L, Zipursky A, Hitzler J. Long-term results of an ultra low-dose cytarabine-based regimen for the treatment of acute megakaryoblastic leukaemia in children with Down syndrome. Br J Haematol. 2006; 133: 646–648
Labuhn M, Perkins K, Matzk S, et al. Mechanisms of Progression of Myeloid Preleukemia to Transformed Myeloid Leukemia in Children with Down Syndrome. Cancer Cell . 2019;36(2):123-138.e10. doi:10.1016/j.ccell.2019.06.007